MarginsXMarginsX
Home › Markets › Health Care › RARE

Ultragenyx Pharmaceutical Inc. (RARE)

RARE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.90
-1.12% on the day
Market cap
$1.6B
Small cap
Revenue · 2025
$673.0M
+20.2% on 2024
Net income · 2025
-$575.0M
-85.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/0001193125-26-057329-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRARE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001515673
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$673.0M
Net income-$575.0M
Operating income-$535.0M
Net margin-85.4%
Operating margin-79.5%
Revenue growth+20.2%
Cash$421.0M
Total assets$1.5B
P/E (computed)Net income was not positive
P/S (computed)2.4×

Warning signs

Cash runway
4.1 months
$150.0M cash at September 30, 2026
Share count, 1 year
+5.6%
2025-10-30 to 2026-10-29 · +24.1% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$4.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$150.0M cash; operating cash flow -$109.3M a quarter.Report 2026-09-30
Shares outstanding101,924,068 (2026-10-29); 96,477,569 a year earlier; 82,114,350 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$173.0M-$118.0M-$43.0M$150.0MNo debt tags$730.0M10-Q 2026-11-04
Q2 2026
2026-06-30
$214.0M-$92.0M-$97.0M$125.0MNo debt tags$717.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$136.0M-$185.0M-$197.0M$175.0MNo debt tags$670.0M10-Q 2026-05-06
Q4 2025
2025-12-31
$207.0M-$129.0M-$100.0M$421.0MNo debt tags$673.0M10-K 2026-02-18
Q3 2025
2025-09-30
$160.0M-$180.0M-$91.0M$203.0MNo debt tags$630.6M10-Q 2026-11-04
Q2 2025
2025-06-30
$167.0M-$115.0M-$109.0M$176.0MNo debt tags$610.1M10-Q 2026-08-05
Q1 2025
2025-03-31
$139.0M-$151.0M-$166.0M$127.0MNo debt tags$590.2M10-Q 2026-05-06
Q4 2024
2024-12-31
$164.6M-$133.2M-$79.3M$174.0MNo debt tags$560.0M10-K 2026-02-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-06-14
Latest annual report10-K2026-02-18
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.2%
1 month+7.8%
3 months-39.0%
Year to date-30.1%
1 year-51.1%
From 52-week high-56.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
PGENPrecigen Inc.$4.30-5.29%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier